SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent
SINTX Technologies (NASDAQ: SINT) has received a USPTO Notice of Allowance for its "Antipathogenic Fibrous Materials" patent application, marking a crucial milestone for its silicon nitride-based antipathogen platform. The patent provides broad protection for using silicon nitride in multiple applications targeting the $30 billion global infection-prevention market.
The technology has demonstrated remarkable efficacy, achieving ~99.97% reduction of multiple coronavirus lineages within 10 minutes and complete inactivation by 30 minutes in laboratory tests. The patent enables applications across medical devices, surgical care, wound management, filtration, PPE, and healthcare infrastructure, addressing the critical challenge of healthcare-associated infections (HAIs) that affect 1 in 31 U.S. hospital patients.
SINTX plans to pursue strategic partnerships and licensing agreements for commercialization, targeting immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, with longer-term applications in implant coatings and filtration media.
SINTX Technologies (NASDAQ: SINT) ha ricevuto una Notifica di Concessione dall'USPTO per la domanda di brevetto "Antipathogenic Fibrous Materials", segnando una tappa fondamentale per la sua piattaforma antipatogena a base di nitruro di silicio. Il brevetto offre una protezione ampia sull'uso del nitruro di silicio in molteplici applicazioni rivolte al mercato globale della prevenzione delle infezioni da 30 miliardi di dollari.
La tecnologia ha mostrato un'efficacia notevole, ottenendo una riduzione di ~99,97% di pi霉 linee di coronavirus in 10 minuti e una completa inattivazione entro 30 minuti nei test di laboratorio. Il brevetto consente applicazioni in dispositivi medici, cure chirurgiche, gestione delle ferite, filtrazione, DPI e infrastrutture sanitarie, affrontando la sfida critica delle infezioni ospedaliere correlate all'assistenza (HAI) che colpiscono 1 paziente su 31 negli ospedali statunitensi.
SINTX intende ricercare partnership strategiche e accordi di licenza per la commercializzazione, puntando a opportunit脿 immediate in medicazioni per ferite, teli chirurgici e ambienti clinici ad alto contatto, con applicazioni a pi霉 lungo termine nei rivestimenti per impianti e nei materiali filtranti.
SINTX Technologies (NASDAQ: SINT) ha recibido una Notificaci贸n de Concesi贸n de la USPTO para su solicitud de patente "Antipathogenic Fibrous Materials", marcando un hito crucial para su plataforma antipat贸gena basada en nitruro de silicio. La patente brinda una amplia protecci贸n para el uso del nitruro de silicio en diversas aplicaciones dirigidas al mercado mundial de prevenci贸n de infecciones de 30.000 millones de d贸lares.
La tecnolog铆a ha demostrado una eficacia notable, logrando una reducci贸n de ~99,97% de m煤ltiples linajes de coronavirus en 10 minutos y una inactivaci贸n completa en 30 minutos en ensayos de laboratorio. La patente permite aplicaciones en dispositivos m茅dicos, cuidados quir煤rgicos, manejo de heridas, filtraci贸n, EPP e infraestructuras sanitarias, abordando el reto cr铆tico de las infecciones asociadas a la atenci贸n sanitaria (HAI) que afectan a 1 de cada 31 pacientes hospitalizados en EE. UU.
SINTX planea buscar asociaciones estrat茅gicas y acuerdos de licencia para la comercializaci贸n, enfoc谩ndose en oportunidades inmediatas en ap贸sitos para heridas, campos quir煤rgicos y entornos cl铆nicos de alto contacto, con aplicaciones a m谩s largo plazo en recubrimientos de implantes y medios filtrantes.
SINTX Technologies (NASDAQ: SINT)電� "Antipathogenic Fibrous Materials" 韸鬼棃於滌洂鞐� 雽�頃� 氙戈淡 韸鬼棃觳�(USPTO)鞙茧攵�韯� 項堦皜 韱奠(Notice of Allowance)毳� 氚涭晿鞙茧┌, 鞚措姅 鞁るΜ旖� 雮橃澊韸鸽澕鞚措摐 旮半皹 頃硲鞗愳泊 頂岆灚韽检棎 鞛堨柎 欷戩殧頃� 鞚挫爼響滌瀰雼堧嫟. 頃措嫻 韸鬼棃電� 350鞏� 雼煬 攴滊鞚� 鞝� 靹戈硠 臧愳椉 鞓堧癌 鞁滌灔鞚� 瓴儱頃� 雼れ枒頃� 鞖╇弰搿� 鞁るΜ旖� 雮橃澊韸鸽澕鞚措摐毳� 靷毄頃橂姅 瓴冹棎 雽�頃� 韽創鞚� 氤错樃毳� 鞝滉车頃╇媹雼�.
鞚� 旮办垹鞚� 鞁ろ棙鞁� 鞁滍棙鞐愳劀 鞐煬 旖旊雮橂皵鞚措煬鞀� 瓿勴喌鞚� 10攵� 雮� 鞎� 99.97% 臧愳唽鞁滍偆瓿� 30攵� 雮� 鞕勳爠 攵堩櫆靹表檾毳� 雼劚頃橂姅 霌� 韮侅洈頃� 須姤鞚� 鞛呾頄堨姷雼堧嫟. 鞚� 韸鬼棃電� 鞚橂旮瓣赴, 鞕戈臣鞝� 觳橃箻, 靸侅矘 甏�毽�, 鞐臣, 臧滌澑氤错樃鞛ル箘(PPE) 氚� 鞚橂 鞚疙攧霛� 鞝勲皹鞐� 鞝侅毄霅� 靾� 鞛堨柎, 氙戈淡 氤戩洂 頇橃瀽 31氇� 欷� 1氇�鞐愱矊 鞓來枼鞚� 氙胳箻電� 鞚橂 甏�霠� 臧愳椉(HAI)鞚措澕電� 欷戨寑頃� 氍胳牅毳� 頃搓舶頃橂姅雿� 旮办棳頃╇媹雼�.
SINTX電� 靸侅毄頇旊ゼ 鞙勴暣 鞝勲灥鞝� 韺岉姼雱堨嫮 氚� 霛检澊靹犾姢 瓿勳暯鞚� 於旍頃� 瓿勴殟鞚措┌, 歃夓嫓 鞝侅毄 臧�電ロ暅 靸侅矘 霌滊爤鞁�, 靾橃垹鞖� 雿皽 氚� 瓿犾爲齑� 鞛勳儊 頇橁步鞚� 鞖办劆鞝侅溂搿� 韮�旯冹溂搿� 頃橁碃, 鞛リ赴鞝侅溂搿滊姅 鞛勴攲霝�韸� 旖旐寘 氚� 鞐臣 毵れ泊搿滌潣 頇曥灔鞚� 氇儔頃橁碃 鞛堨姷雼堧嫟.
SINTX Technologies (NASDAQ: SINT) a re莽u une Notice of Allowance de l'USPTO pour sa demande de brevet 芦 Antipathogenic Fibrous Materials 禄, marquant une 茅tape cl茅 pour sa plateforme antipathog猫ne 脿 base de nitrure de silicium. Le brevet offre une protection 茅tendue pour l'utilisation du nitrure de silicium dans de multiples applications visant le march茅 mondial de pr茅vention des infections de 30 milliards de dollars.
La technologie a d茅montr茅 une efficacit茅 remarquable, obtenant une r茅duction d'environ 99,97 % de plusieurs lign茅es de coronavirus en 10 minutes et une inactivation compl猫te en 30 minutes lors des tests en laboratoire. Le brevet permet des applications dans les dispositifs m茅dicaux, les soins chirurgicaux, la gestion des plaies, la filtration, les EPI et les infrastructures de sant茅, r茅pondant au d茅fi majeur des infections associ茅es aux soins (HAI) qui touchent 1 patient sur 31 dans les h么pitaux am茅ricains.
SINTX pr茅voit de rechercher des partenariats strat茅giques et des accords de licence pour la commercialisation, ciblant des opportunit茅s imm茅diates pour les pansements, les champs chirurgicaux et les environnements cliniques 脿 contact 茅lev茅, avec des applications 脿 plus long terme pour les rev锚tements d'implants et les m茅dias filtrants.
SINTX Technologies (NASDAQ: SINT) hat eine Notice of Allowance des USPTO f眉r seine Patentanmeldung "Antipathogenic Fibrous Materials" erhalten und damit einen entscheidenden Meilenstein f眉r seine antipathogene Plattform auf Siliziumnitrid-Basis erreicht. Das Patent bietet weitreichenden Schutz f眉r den Einsatz von Siliziumnitrid in verschiedenen Anwendungen des 30 Milliarden Dollar schweren weltweiten Marktes f眉r Infektionspr盲vention.
Die Technologie zeigte in Labortests eine bemerkenswerte Wirksamkeit: eine ~99,97%ige Reduktion mehrerer Coronavirus-Linien innerhalb von 10 Minuten und eine vollst盲ndige Inaktivierung nach 30 Minuten. Das Patent erm枚glicht Anwendungen in medizinischen Ger盲ten, chirurgischer Versorgung, Wundmanagement, Filtration, PSA und Gesundheitsinfrastruktur und adressiert die wichtige Herausforderung nosokomialer Infektionen (HAIs), die 1 von 31 Patienten in US-Krankenh盲usern betreffen.
SINTX plant, strategische Partnerschaften und Lizenzvereinbarungen zur Kommerzialisierung anzustreben und fokussiert sich auf kurzfristige Chancen bei Wundverb盲nden, chirurgischen Abdeckungen und klinischen Bereichen mit hoher Kontaktfrequenz sowie langfristig auf Implantatbeschichtungen und Filtermedien.
- Patent secures broad protection for silicon nitride-based antipathogen platform in the $30B+ infection-prevention market
- Technology demonstrates 99.97% coronavirus reduction in 10 minutes with complete inactivation by 30 minutes
- Multiple immediate commercial applications in wound dressings, surgical drapes, and healthcare environments
- Potential to significantly reduce healthcare costs, with HAI cases currently costing $14,000-$48,000 per incident
- Clinical validation still pending for commercial applications
- Market adoption and strategic partnerships yet to be secured
- Commercialization timeline and revenue potential remain uncertain
Insights
SINTX secures crucial patent for silicon nitride technology that could transform infection prevention in a $30B market.
SINTX Technologies has received a Notice of Allowance from the USPTO for its silicon nitride-based antipathogen platform patent, representing a critical intellectual property milestone. This patent provides broad protection for the company's technology across multiple applications designed to neutralize pathogens on contact.
The significance of this development cannot be overstated. It positions SINTX in the estimated
What makes this particularly valuable is the versatility of applications. The company can now pursue opportunities in wound management, surgical care, PPE, filtration, and healthcare infrastructure - all protected under a single patent family. This creates substantial defensive moats against competitors while establishing multiple commercialization pathways.
The company has built this patent on a foundation of peer-reviewed science demonstrating silicon nitride's antimicrobial properties, including recent studies showing it can inactivate multiple coronavirus lineages with
SINTX's commercialization strategy appears well-considered, focusing on strategic partnerships and licensing agreements rather than direct manufacturing. This approach leverages their IP without requiring massive capital investments, potentially creating recurring revenue streams across multiple market segments.
The USPTO allowance for SINTX's silicon nitride antipathogenic platform represents a substantial value inflection point for this small-cap medical technology company. The patent secures protection for a technology platform with applications across a
Looking at the competitive landscape, SINTX has established a differentiated position with their silicon nitride technology. Unlike conventional infection-control approaches that rely on antimicrobial chemicals, drugs, or surface treatments with limited durability, SINTX's platform offers continuous, passive, drug-free pathogen inactivation embedded directly into materials.
The financial implications are compelling. Healthcare-associated infections (HAIs) impose significant economic burdens, with per-case costs ranging from
SINTX's strategic approach focusing on partnerships and licensing agreements represents a capital-efficient commercialization pathway. This model could potentially generate high-margin revenue streams without the substantial manufacturing investments typically required for medical device commercialization.
The breadth of this patent creates optionality for the company 鈥� they can pursue multiple market opportunities simultaneously through different partnership arrangements, potentially accelerating their path to significant revenue while diversifying commercial risk across various applications and partners.
Significant Development in the Estimated
SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (鈥淪INTX鈥� or the 鈥淐ompany鈥�), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, 鈥�Antipathogenic Fibrous Materials.鈥� The patent secures broad protection for SINTX鈥檚 proprietary silicon nitride鈥揵ased antipathogen platform.
This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neutralize pathogens at the point of contact. The patent establishes a foundation for further infection-resistant innovation in medical devices, surgical care, wound management, filtration and PPE, and healthcare infrastructure 鈥� segments of a global infection-prevention market estimated to exceed
Leadership Perspective
鈥淲e believe this is a defining moment for SINTX. This patent has the potential to elevate silicon nitride from a proven biomaterial into a true platform technology for infection prevention,鈥� stated Eric K. Olson, Chairman, President & CEO of SINTX Technologies. 鈥淭he protection we鈥檝e secured will enable us to engineer silicon nitride into coatings, textiles, dressings, filters, and device surfaces鈥攕olutions that can lower infection risk, shorten hospital stays, reduce healthcare costs, and most importantly, save lives. We believe it is transformative for patients and a potential catalyst for long-term shareholder value.鈥�
Why It Matters for Patients and the Healthcare System
Healthcare-associated infections (HAIs) remain one of the costliest and most persistent challenges in medicine. According to the CDC, 1 in 31 U.S. hospital patients has an HAI on any given day. Studies estimate tens of billions of dollars in annual direct costs, with per-case expenses ranging from ~
By providing continuous, passive, drug-free pathogen inactivation, silicon nitride has the potential鈥攑ending clinical validation and adoption鈥攖o reduce infection incidence at scale. Even modest reductions could translate into billions in savings for hospitals and payers while improving outcomes globally.
Built on Decades of Peer-Reviewed Science
This milestone builds on more than a decade of evidence demonstrating silicon nitride鈥檚 antimicrobial and antibiofilm properties. Most recently, SINTX and academic collaborators reported that silicon nitride inactivated multiple lineages of SARS-CoV-2 and MERS-CoV coronaviruses during standardized in vitro plaque assays within minutes, achieving ~
鈥淭he allowed claims support what our data already show: silicon nitride can be engineered into surfaces of products that actively neutralize pathogens,鈥� said Dr. Ryan Bock, Chief Technology Officer. 鈥淭his important patent affords the Company to seek immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, alongside longer-term applications in implant coatings and filtration media.鈥�
Expanding a Robust IP Estate
This Notice of Allowance expands SINTX鈥檚 intellectual-property portfolio into a comprehensive antipathogen platform deployable across nearly every high-risk healthcare setting. It complements existing granted patents on antipathogenic face masks, systems for rapid viral inactivation, and advanced processing of silicon nitride ceramics for biomedical applications.
Commercialization Path and Market Impact
SINTX intends to pursue strategic partnerships, licensing agreements, and co-development programs with manufacturers of wound dressings, PPE, implant-adjacent components, filters, and healthcare infrastructure. The patent鈥檚 breadth of coverage, combined with silicon nitride鈥檚 manufacturing scalability and seamless integration into existing workflows, creates a rapid path to adoption without requiring disruptive infrastructure changes.
Looking Ahead
With this patent allowance, SINTX is positioned to accelerate product commercialization, expand its footprint in the estimated
鈥淲e fundamentally believe this patent may represent a paradigm shift for both patient care and our Company鈥檚 commercial trajectory,鈥� Olson added. 鈥淚t underscores the unique role SINTX can play in shaping the future of infection prevention worldwide with a biomaterial that matters.鈥�
References
(Please see below references to sources above for scientific data, prevalence and cost contexts.)
- ;
- ;
- ;
- ;
- ;
- /news/SINT/sintx-technologies-publishes-landmark-study-demonstrating-broad-tpgo9g531m4t.html?utm_source=chatgpt.com;
- ;
- ;
- ;
- ;
- ;
- ;
For more information, visit .
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Through innovation and strategic partnerships, SINTX continues to expand its portfolio across multiple markets. For more information on SINTX Technologies or its materials platform, visit聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding: the potential benefits of the newly allowed patent, including the technology鈥檚 potential impact on infection prevention, patient outcomes, healthcare costs, and shareholder value; expectations for commercialization, market adoption, and strategic partnerships; and SINTX鈥檚 ability to expand its presence in the infection-prevention market. Forward-looking statements are based on current expectations, estimates, and projections about future events and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ materially include, but are not limited to, risks related to regulatory approvals, manufacturing scale-up, market acceptance, competition, intellectual property protection, and other risks detailed in SINTX鈥檚 filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. SINTX disclaims any obligation to update these forward-looking statements, except as required by law.
Business and Media Inquiries for SINTX:
Elliot Sloane
ThroughCo Communications
917-291-0833
Katie Russo
ThroughCo Communications
501-282-5069
SINTX Technologies, Inc.
801.839.3502
FAQ
What is the significance of SINTX Technologies' new patent allowance?
How effective is SINTX's silicon nitride technology against pathogens?
What are the potential applications for SINTX's antipathogenic technology?
How could SINTX's technology impact healthcare costs?
What are SINTX's commercialization plans for this technology?
